These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

441 related items for PubMed ID: 33637602

  • 1. CXCL9-expressing tumor-associated macrophages: new players in the fight against cancer.
    Marcovecchio PM, Thomas G, Salek-Ardakani S.
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637602
    [Abstract] [Full Text] [Related]

  • 2. Microwave ablation combined with PD-L1 blockade synergistically promotes Cxcl9-mediated antitumor immunity.
    He N, Huang H, Wu S, Ji W, Tai Y, Gao R, Liu Y, Liu Y, Chen L, Zhu D, Zheng X, Jiang J.
    Cancer Sci; 2024 Jul; 115(7):2196-2208. PubMed ID: 38655660
    [Abstract] [Full Text] [Related]

  • 3. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
    House IG, Savas P, Lai J, Chen AXY, Oliver AJ, Teo ZL, Todd KL, Henderson MA, Giuffrida L, Petley EV, Sek K, Mardiana S, Gide TN, Quek C, Scolyer RA, Long GV, Wilmott JS, Loi S, Darcy PK, Beavis PA.
    Clin Cancer Res; 2020 Jan 15; 26(2):487-504. PubMed ID: 31636098
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond.
    Karin N.
    Front Immunol; 2020 Jan 15; 11():976. PubMed ID: 32547545
    [Abstract] [Full Text] [Related]

  • 9. Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.
    Dangaj D, Bruand M, Grimm AJ, Ronet C, Barras D, Duttagupta PA, Lanitis E, Duraiswamy J, Tanyi JL, Benencia F, Conejo-Garcia J, Ramay HR, Montone KT, Powell DJ, Gimotty PA, Facciabene A, Jackson DG, Weber JS, Rodig SJ, Hodi SF, Kandalaft LE, Irving M, Zhang L, Foukas P, Rusakiewicz S, Delorenzi M, Coukos G.
    Cancer Cell; 2019 Jun 10; 35(6):885-900.e10. PubMed ID: 31185212
    [Abstract] [Full Text] [Related]

  • 10. IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors.
    Beyranvand Nejad E, Labrie C, van Elsas MJ, Kleinovink JW, Mittrücker HW, Franken KLMC, Heink S, Korn T, Arens R, van Hall T, van der Burg SH.
    J Immunother Cancer; 2021 Apr 10; 9(4):. PubMed ID: 33879600
    [Abstract] [Full Text] [Related]

  • 11. LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy.
    Pascual-García M, Bonfill-Teixidor E, Planas-Rigol E, Rubio-Perez C, Iurlaro R, Arias A, Cuartas I, Sala-Hojman A, Escudero L, Martínez-Ricarte F, Huber-Ruano I, Nuciforo P, Pedrosa L, Marques C, Braña I, Garralda E, Vieito M, Squatrito M, Pineda E, Graus F, Espejo C, Sahuquillo J, Tabernero J, Seoane J.
    Nat Commun; 2019 Jun 11; 10(1):2416. PubMed ID: 31186412
    [Abstract] [Full Text] [Related]

  • 12. Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade.
    Wakita D, Iwai T, Harada S, Suzuki M, Yamamoto K, Sugimoto M.
    Anticancer Res; 2019 Apr 11; 39(4):1749-1760. PubMed ID: 30952714
    [Abstract] [Full Text] [Related]

  • 13. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
    Lacal PM, Atzori MG, Ruffini F, Scimeca M, Bonanno E, Cicconi R, Mattei M, Bernardini R, D'Atri S, Tentori L, Graziani G.
    Pharmacol Res; 2020 Sep 11; 159():104957. PubMed ID: 32485280
    [Abstract] [Full Text] [Related]

  • 14. CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression.
    Gao HF, Cheng CS, Tang J, Li Y, Chen H, Meng ZQ, Chen Z, Chen LY.
    Aging (Albany NY); 2020 Jan 08; 12(1):502-517. PubMed ID: 31913856
    [Abstract] [Full Text] [Related]

  • 15. Obesity induces PD-1 on macrophages to suppress anti-tumour immunity.
    Bader JE, Wolf MM, Lupica-Tondo GL, Madden MZ, Reinfeld BI, Arner EN, Hathaway ES, Steiner KK, Needle GA, Hatem Z, Landis MD, Faneuff EE, Blackman A, Wolf EM, Cottam MA, Ye X, Bates ME, Smart K, Wang W, Pinheiro LV, Christofides A, Smith D, Boussiotis VA, Haake SM, Beckermann KE, Wellen KE, Reinhart-King CA, Serezani CH, Lee CH, Aubrey C, Chen H, Rathmell WK, Hasty AH, Rathmell JC.
    Nature; 2024 Jun 08; 630(8018):968-975. PubMed ID: 38867043
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T, Fuangthong M, Artpradit C, Ungtrakul T, Sricharunrat T, Taha F, Satayavivad J.
    Eur J Pharmacol; 2021 Apr 15; 897():173960. PubMed ID: 33617828
    [Abstract] [Full Text] [Related]

  • 17. LINC00152 mediates CD8+ T-cell infiltration in gastric cancer through binding to EZH2 and regulating the CXCL9, 10/CXCR3 axis.
    Ou J, Lei P, Yang Z, Yang M, Luo L, Mo H, Luo G, He J.
    J Mol Histol; 2021 Jun 15; 52(3):611-620. PubMed ID: 33709190
    [Abstract] [Full Text] [Related]

  • 18. Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy.
    Chow MT, Ozga AJ, Servis RL, Frederick DT, Lo JA, Fisher DE, Freeman GJ, Boland GM, Luster AD.
    Immunity; 2019 Jun 18; 50(6):1498-1512.e5. PubMed ID: 31097342
    [Abstract] [Full Text] [Related]

  • 19. Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function.
    Petty AJ, Dai R, Lapalombella R, Baiocchi RA, Benson DM, Li Z, Huang X, Yang Y.
    JCI Insight; 2021 Mar 22; 6(6):. PubMed ID: 33749663
    [Abstract] [Full Text] [Related]

  • 20. Blockade of C5a receptor unleashes tumor-associated macrophage antitumor response and enhances CXCL9-dependent CD8+ T cell activity.
    Luan X, Lei T, Fang J, Liu X, Fu H, Li Y, Chu W, Jiang P, Tong C, Qi H, Fu Y.
    Mol Ther; 2024 Feb 07; 32(2):469-489. PubMed ID: 38098230
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.